Changes in cerebral function parameters in HIV type 1-infected subjects switching to darunavir/ritonavir either as monotherapy or with nucleoside analogues.
Lucy
L
Garvey
Chris
C
Higgs
Perry
P
Mohammed
Andrew
A
Hill
Joanna M
JM
Allsop
Simon D
SD
Taylor-Robinson
Mark
M
Nelson
Alan
A
Winston
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001921:Brain / Q000187:drug effects* / Q000502:physiology; D001928:Brain Diseases, Metabolic / Q000139:chemically induced*; D000069454:Darunavir; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008131:London; D008297:Male; D009705:Nucleosides / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*
D019380:Anti-HIV Agents; D009705:Nucleosides; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir